Canopy Growth Corp vs DuPont de Nemours Inc — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while DuPont de Nemours Inc trades at $144.72 (market cap $19.51B). The key difference: DuPont de Nemours Inc is far larger — about 46.3× Canopy Growth Corp's market cap, and DuPont de Nemours Inc pays a 1.66% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | DD | |
|---|---|---|
Market Cap | $421.10M | $19.51B |
Sector | Health | Basic Materials |
52-Week High | $1.92 | $154.59 |
52-Week Low | $0.86 | $90.24 |
Enterprise Value | $378.55M | $20.90B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
DuPont (DD) trades at $143.64, up 1.47% today, with strong technical momentum as price approaches resistance near $146. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.88 exceeding the $1.76 estimate, and raised full-year 2026 guidance. Recent news highlights contract wins in water treatment and R&D innovation awards, though the stock faces valuation concerns with a P/E of 62 and negative net income in 2025.
The outlook is cautiously optimistic given earnings momentum and analyst bullishness (58% buy ratings), but high valuation and thin profit margins pose risks. The consensus price target of $232.80 suggests significant upside if execution continues, though investors should monitor debt levels and PFAS litigation developments that could impact financials.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →